We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Arbutus Biopharma Corporation is among the best biotech stocks under $10 to buy.
TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $7.00 to $5.50 while maintaining a Buy rating. The revision was driven by updated expectations around the outcome of Moderna’s appeal in ongoing litigation, which could influence a potential $1.3 billion payment tied to the case. The firm adjusted its probability assessment, increasing the likelihood of a Moderna win on appeal, which in turn reduced its valuation outlook for ABUS.
On March 23, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported its fourth-quarter and full-year 2025 financial results and provided a corporate update. The company highlighted its ongoing litigation-related developments, including a settlement agreement with Moderna and Genevant under which ABUS is entitled to a portion of a $950 million upfront payment expected in July 2026, along with potential eligibility for an additional $1.3 billion contingent on an appellate outcome.
It also noted continued legal proceedings involving its lipid nanoparticle intellectual property. For the year, the business reported revenue of $14.1 million, net loss of $33.5 million, cash and investments of $91.5 million, and reduced operating expenses driven by restructuring and cost optimization efforts focused on its clinical pipeline.
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases. It is particularly known for its work in hepatitis B treatments, using RNA interference and lipid nanoparticle delivery technologies to target and suppress viral replication.
READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.
